Post by dabebe on Sept 4, 2015 10:23:41 GMT
Paliperidone is an atypical antipsychotic. Paliperidone (trade name Invega), also known as 9-hydroxyrisperidone, is a dopamine antagonist and 5-HT2Aantagonist. Invega is an extended release formulation of paliperidone that uses extended release system to allow for once-daily dosing. Paliperidone palmitate is a long-acting injectable formulation of paliperidone palmitoyl ester indicated for once-monthly injection after an initial titration period. Paliperidone is used to treat mania and at lower doses as maintenance for bipolar disorder. It is also used for schizophrenia and schizoaffective disorder.
Side effect
Common side effects (5-10%). Headache, tachycardia, somnolence (causes less sedation than most atypical antipsychotic insomnia and hyperprolactinaemia. There are less comommon side effects (1-5%) and include cough, extrapyramidal side effects (EPSE; e.g. dystonia, akathisia, muscle rigidity, parkinsonism), orthostatic hypotension, weight gain nasopharyngitis, anxiety, indigestion and constipation.
Dosage:
INVEGA (paliperidone) extended-release tablets are available in 1.5-mg (orange-brown), 3-mg (white), 6-mg (beige), and 9-mg (pink) strengths. INVEGA dose adjustment should only occur after clinical reassessment and should occur at intervals of more than:
• 4 days for patients with schizoaffective disorder, and
• 5 days for patients with schizophrenia
The 1.5-mg strength of INVEGA® is the recommended initial once-daily dose for patients with moderate to severe renal impairment. For mild renal impairment, the recommended initial INVEGA® dose is 3 mg once daily
Contraindications:
It is contraindicated in patients with proved for the treatment of patients with dementia-related psychosis. It is also not recommended in patients who have/developed cerebrovascular accident or patients who had cardiac arrhythmias.